Infectious Diseases

Overview

The groups of this area aim to improve the outcomes of patients with infectious diseases. The Epidemiology and Public Health group focuses on the epidemiology and prevention of healthcare acquired infections, transmissible infections and on the new vaccines. The Infectious Diseases group focuses on improving the strategies of clinical problems observed in clinical practice. The Microbiology group studies the mechanisms of antimicrobial resistance, pathogenicity, genomic epidemiology and infectious diseases diagnostics. The CRIPS group focuses on developing translational and clinical research in critical care, while the SODIR group works in the areas of sepsis, organ dysfunction and resuscitation. There is also a group focused on clinical research on children’s infectious diseases and primary immunodeficiencies. Finally, the CIBBIM-Nanomedicine group Works in the synthesis, characterization and applications of engineered inorganic nanoparticles in the field of infectious diseases.

Publications

260

total

1322

impact factor

5.08

average impact factor

Group Leader: Magda Campins Martí

team

group-zoom

zoom

group-download

download

Among the highlights of 2019, we have expanded our research line on vaccines and on chronic disease epidemiology. For the first, we have set up a prospective registry of vaccination in patients with Immuno-mediated inflammatory disease (IMID) who are candidates for biological treatment with the aim of evaluating vaccine immunogenicity and safety that will allow establishing the best vaccination strategy. For the second, we will study the prevalence and impact of comorbidity on Multiple Sclerosis prognosis.

As for clinical trials, our group has expanded its line of research on the adjuvanted recombinant Herpes Zoster vaccine testing its safety and immunogenicity in pediatric immunosuppressed patients and adults ?50 years of age with a prior episode of Herpes Zoster. Our team has also started a new line of investigation for a Respiratory Syncytial Virus vaccine in healthy pregnant women

18

total

111

impact factor

6^.17

average impact factor

SELECTED ARTICLES

Xavier Martínez-Gómez, Adrian Curran, Magda Campins, Laia Alemany, José Ángel Rodrigo-Pendás, Natalia Borruel , Xavier Castellsagué, Cristina Díaz-de-Heredia, Fernando A Moraga-Llop, Marta Del Pino, Aureli Torné.
Multidisciplinary, Evidence-Based Consensus Guidelines for Human Papillomavirus (HPV) Vaccination in High-Risk Populations, Spain, 2016.
Euro Surveill. 2019 Feb;24(7):1700857.
DOI: 10.2807/1560-7917.ES.2019.24.7.1700857
IF: 7,42
Magda Campins Martí, Blanca Borrás Bermejo, Lluis Armadans Gil.
Infections With Mycobacterium Chimaera and Open Chest Surgery. An Unresolved Problem.
Med Clin (Barc). 2019 Apr 18;152(8):317-323.
DOI: 10.1016/j.medcli.2018.10.013
IF: 1,28
María I Zuluaga, Susana Otero-Romero, Alex Rovira, Santiago Perez-Hoyos, Georgina Arrambide, Laura Negrotto , Ingrid Galán , Jordi Río , Manuel Comabella , Carlos Nos , María Jesús Arévalo , Angela Vidal-Jordana , Joaquin Castilló , Breogán Rodríguez , Luciana Midaglia , Patricia Mulero , Raquel Mitjana , Cristina Auger , Jaume Sastre-Garriga , Xavier Montalban , Mar Tintoré.
Menarche, Pregnancies, and Breastfeeding Do Not Modify Long-Term Prognosis in Multiple Sclerosis.
Neurology. 2019 Mar 26;92(13):e1507-e1516. Epub 2019 Mar.
DOI: 10.1212/WNL.0000000000007178
IF: 8,69
Mir-Cros A, Moreno-Mingorance A, Martín-Gómez MT, Codina G, Cornejo-Sánchez T, Rajadell M, Van Esso D, Rodrigo C, Campins M, Jané M, Pumarola T, Fàbrega A, González-López JJ.
Population dynamincs and antigenic drift of Bordetella pertussis following whole cell vaccine replacement, Barcelona, Spain, 1986-2015.
Emerg Microbes Infect. 2019;8(1):1711-1720.
DOI: 10.1080/22221751.2019.1694395.
IF: 6,21
Andrés C, Peremiquel-Trillas P, Gimferrer L, Piñana M, Codina MG, Rodrigo-Pendás JÁ, Campins-Martí M, Carmen Martín M, Fuentes F, Rubio S, Pumarola T, Antón A.
Molecular influenza surveillance at a tertiary university hospital during four consecutive seasons (2012-2016) in Catalonia, Spain.
Vaccine. 2019 Apr 24;37(18):2470-2476.
DOI: 10.1016/j.vaccine.2019.03.046.
IF: 3,27

View all publications

A phase II observer-blind study to assess safety, reactogenicity, and immunogenicity of GSK Biologicals’ investigational RSV Maternal unadjuvanted vaccine (GSK3888550A), in healthy pregnant women and infants born to vaccinated mothers. 209544 (RSV MAT-004).
Funding: GlaxoSmithKline
Principal investigator: Xavier Martínez and Elena Carreras
Period: 2019 to date.
A phase III, randomized, observer-blind, placebo controlled, multicentre clinical trial to assess Herpes Zoster recurrence, safety, reactogenicity and immunogenicity of GSK Biologicals’ Herpes Zoster (HZ/su) vaccine when administered intramuscularly on a 0 and 2 month schedule to adults ?50 years of age with a prior episode of Herpes Zoster. 204939 (ZOSTER-062).
Funding: GlaxoSmithKline
Principal investigator: Xavier Martínez
Period: 2019 to date
A phase II, randomized, open-label, multicentre study to assess the safety, reactogenicity and immunogenicity of GSK Biologicals’ paediatric Herpes Zoster subunit candidate vaccine (PED-HZ/su) when administered intramuscularly on a two-dose schedule to IC paediatric renal transplant recipiemts from to 7 years of age. 200075 (ZOSTER-047).
Funding: GlaxoSmithKline
Principal investigator: Xavier Martínez
Period: 2019 to date
Passive enhanced safety surveillance of GSK’s quadrivalent seasonal influenza vaccines: a pilot study in Belgium, Germany and Spain during the 209/20 influenza season. 207749 (EPI-FLU-057 VS EU).
Funding: GlaxoSmithKline
Principal investigator: Xavier Martínez
Period: 2019 to 2020
A phase IV, low level intervention, clinical trial to compare the immunogenicity of an adjuvanted anti-hepatitis B vaccine with the one with increased antigenic load in immunosuppressed patients.
Funding: Instituto de Salud Carlos III (project number: PI8/0887)
Principal investigators: Magda Campins and Lluis Armadans
Period: 2018 to 2021

[ View all projects ]